EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.296
https://www.valueinhealthjournal.com/article/S1098-3015(22)02500-1/fulltext
Title :
EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02500-1&doi=10.1016/j.jval.2022.09.296
First page :
Section Title :
Open access? :
No
Section Order :
12103